Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Blood pressure and transcranial ultrasound predict moyamoya vasculopathy in Down syndrome.

Created on 30 Sep 2026

Authors

Jonathan D Santoro, Mackenzie Silverman, Benjamin N Vogel, Bryan T Lei, Ramon Durazo-Arvizu, Sarah Lee, Elizabeth W Mayne, Brian G Skotko, Pat Levitt, Michael S Rafii

Published in

Developmental medicine and child neurology. Sep 29, 2026. Epub Sep 29, 2026.

Abstract

To evaluate the feasibility of a stepwise, non-invasive screening framework integrating blood pressure measurement with transcranial Doppler ultrasonography.
In this prospective single-site cohort study, 793 individuals with Down syndrome aged 8 to 26 years underwent standardized blood pressure assessment. Comparisons with National Health and Nutrition Examination Survey 2017-2018 were restricted to participants aged 8 years to younger than 18 years and performed using survey-weighted regression. A smaller cohort of 111 participants underwent repeat blood pressure assessment, awake transcranial Doppler ultrasonography, and confirmatory magnetic resonance imaging/angiography.
Among 988 screened participants, 793 were enrolled (mean age 16 years 7 months [SD 4 years 6 months]; 414 females, 378 males, and one participant of unknown sex). Mean systolic blood pressure centile was 44.7 in Down syndrome and 42.6 in the comparison cohort (difference 2.07 points, 95% confidence interval [CI] -1.12 to 5.26; p = 0.200). Diastolic blood pressure centile was higher in Down syndrome (difference 12.21 points, 95% CI 8.88-15.53; p < 0.001). Of the 111 participants who completed transcranial Doppler ultrasonography, 10 required repeat acquisition. Higher blood pressure was associated with higher mean middle cerebral artery velocity (75.5 vs 65.7 cm/s; p = 0.006). Imaging identified asymptomatic moyamoya syndrome in four participants.
A stepwise approach incorporating blood pressure and transcranial Doppler ultrasonography is feasible for cerebrovascular surveillance in Down syndrome. These findings support development of scalable screening strategies and warrant multicenter validation.

PMID:
42809670
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 18
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement